LaSalle St. Investment Advisors LLC Takes $416,000 Position in Thermo Fisher Scientific Inc. $TMO

LaSalle St. Investment Advisors LLC bought a new stake in Thermo Fisher Scientific Inc. (NYSE:TMO) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund bought 829 shares of the medical research company’s stock, valued at approximately $416,000.

A number of other institutional investors have also made changes to their positions in TMO. Elyxium Wealth LLC increased its stake in Thermo Fisher Scientific by 1.9% in the 4th quarter. Elyxium Wealth LLC now owns 1,058 shares of the medical research company’s stock valued at $613,000 after buying an additional 20 shares during the last quarter. Revolve Wealth Partners LLC raised its holdings in Thermo Fisher Scientific by 4.2% during the fourth quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company’s stock worth $255,000 after acquiring an additional 20 shares in the last quarter. Holt Capital Advisors L.L.C. dba Holt Capital Partners L.P. raised its stake in shares of Thermo Fisher Scientific by 0.7% during the 3rd quarter. Holt Capital Advisors L.L.C. dba Holt Capital Partners L.P. now owns 2,960 shares of the medical research company’s stock worth $1,436,000 after purchasing an additional 20 shares in the last quarter. Confluence Wealth Services Inc. grew its stake in shares of Thermo Fisher Scientific by 0.5% in the fourth quarter. Confluence Wealth Services Inc. now owns 4,292 shares of the medical research company’s stock valued at $2,487,000 after buying an additional 22 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. raised its position in Thermo Fisher Scientific by 0.6% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 3,985 shares of the medical research company’s stock worth $2,311,000 after acquiring an additional 22 shares in the last quarter. Institutional investors own 89.23% of the company’s stock.

Insider Activity

In other Thermo Fisher Scientific news, CAO Joseph R. Holmes sold 420 shares of Thermo Fisher Scientific stock in a transaction dated Friday, August 7th. The stock was sold at an average price of $584.81, for a total transaction of $245,620.20. Following the completion of the transaction, the chief accounting officer owned 2,966 shares in the company, valued at approximately $1,734,546.46. The trade was a 12.40% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Lisa P. Britt sold 11,440 shares of the firm’s stock in a transaction that occurred on Wednesday, August 19th. The shares were sold at an average price of $613.12, for a total value of $7,014,092.80. Following the completion of the transaction, the vice president owned 14,784 shares in the company, valued at $9,064,366.08. This represents a 43.62% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 63,493 shares of company stock valued at $37,657,681. 0.33% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on TMO. Royal Bank Of Canada raised their target price on shares of Thermo Fisher Scientific from $490.00 to $580.00 and gave the company a “sector perform” rating in a research note on Friday, July 24th. Barclays raised their price target on Thermo Fisher Scientific from $625.00 to $650.00 and gave the company an “overweight” rating in a report on Friday, July 24th. HSBC cut shares of Thermo Fisher Scientific from a “buy” rating to a “hold” rating and cut their target price for the stock from $670.00 to $540.00 in a research note on Wednesday, June 3rd. Morgan Stanley boosted their price objective on Thermo Fisher Scientific from $620.00 to $650.00 and gave the stock an “overweight” rating in a report on Friday, July 24th. Finally, KeyCorp reaffirmed an “overweight” rating on shares of Thermo Fisher Scientific in a research report on Tuesday, May 26th. One analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and six have assigned a Hold rating to the stock. Based on data from MarketBeat.com, Thermo Fisher Scientific currently has an average rating of “Moderate Buy” and an average target price of $619.41.

Thermo Fisher Scientific Stock Performance

Shares of TMO opened at $628.24 on Friday. The stock has a market capitalization of $232.29 billion, a P/E ratio of 33.79, a price-to-earnings-growth ratio of 2.50 and a beta of 0.85. The firm’s fifty day simple moving average is $539.33 and its two-hundred day simple moving average is $508.86. The company has a current ratio of 1.55, a quick ratio of 1.18 and a debt-to-equity ratio of 0.74. Thermo Fisher Scientific Inc. has a 12 month low of $435.27 and a 12 month high of $643.99.

Thermo Fisher Scientific (NYSE:TMO) last issued its earnings results on Thursday, July 23rd. The medical research company reported $6.03 EPS for the quarter, beating the consensus estimate of $5.71 by $0.32. The company had revenue of $11.99 billion during the quarter, compared to the consensus estimate of $11.71 billion. Thermo Fisher Scientific had a return on equity of 17.09% and a net margin of 15.04%.The firm’s revenue for the quarter was up 10.5% compared to the same quarter last year. During the same period last year, the business posted $4.28 EPS. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. As a group, analysts predict that Thermo Fisher Scientific Inc. will post 25.12 EPS for the current year.

Thermo Fisher Scientific Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, October 15th. Investors of record on Tuesday, September 15th will be issued a $0.47 dividend. This represents a $1.88 dividend on an annualized basis and a dividend yield of 0.3%. The ex-dividend date is Tuesday, September 15th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is currently 10.11%.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.